首页 产品中心
  • INF39
    • INF-39
    货号: abs822874
    CAS号: 866028-26-4
    分子式: C12H13ClO2
    分子量: 224.68
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs822874-5mg 4周 ¥2413.00
    - +
    大包装询价
    产品描述
    描述

    INF39 is an irreversible and noncytotoxic NLRP3 inhibitor.

    纯度
    98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    INF-39
    外观
    colorless to light brown oil
    可溶性/溶解性
    DMSO : 1 mg/mL (4.45 mM; Need ultrasonic)
    生物活性
    In vitro(体外研究)
    INF39 is able to significantly inhibit ATP- and nigericin-induced IL-1β release at 10 μM. INF39 reduces caspase-1 activation and pyroptosis in the macrophages. INF39 can block not only NLRP3 activation but also the NF-κB pathway. INF39 potentially reacts with Cys-SH residues in the active site of cysteine protease caspase-1, but does not directly target caspase-1 activity. INF39 is able to reduce the steady state (or basal) BRET signal of NLRP3 without affecting the viability of cells, meaning that it can interfere with the basal NLRP3 conformation. INF39 does not block the initial conformational changes suffered by NLRP3 upon sensing the decrease of intracellular K+; however, it affects a second step of NLRP3 conformational change that could be related with the ATPase activity of the receptor and be independent of the decrease of intracellular K+. INF39 reaches the intestinal epithelium without undergoing chemical modifications. After absorption into epithelial cells, it is likely to act locally at the mucosal epithelial level.
    In vivo(体内研究)
    Oral administration of INF39 reduces systemic and colonic inflammation in rats treated with 2,4- dinitrobenzenesulfonic acid. Significant increments of body weight are observed in inflamed rats under treatment with INF39 (12.5, 25, and 50 mg/ kg). Treatment with DNBS results in a significant increment of spleen weight (+39.3%). Such an increase is significantly reduced by administration of INF39 (+2.2, +4.3 and +4.8% at 12.5, 25, 50 mg/kg, respectively). The inhibition of NLRP3 inflammasome complex with INF39 dose-dependently attenuates the decrease in colonic length (−19, −13 and −8% at 12.5, 25, 50 mg/kg, respectively). Rats treated with INF39 displays a significant reduction of macroscopic damage score (4.7 at 12.5 mg/kg, 3.1 at 25 mg/kg, and 2.8 at 50 mg/kg). Oral administration of INF39 reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要提问

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0